SEC 13F Intelligence

Managers / Q1 2026

5AM Venture Management, LLC

CIK 0001799883 · 4 EMBARCADERO CENTER, SUITE 3110, SAN FRANCISCO, CA, 94111 · (415) 993-8565

Reported Value
$360M
Q1 2026
Positions
20
Filings on Record
26
2019–present window
Filed
May 15, 2026
original filing

Summary

5am Venture Management, LLC reported $360M in U.S.-listed holdings across 20 positions for Q1 2026.

Its largest position, ERAS, represents 15.7% of the portfolio.

Compared with Q4 2025, the fund opened 2 new positions and exited 3.

Portfolio Metrics

Turnover
+16.8%
vs prior filed quarter
Top-10 Concentration
+79.8%
share of reported value
Largest Position
+15.7%
Erasca
New / Exited
2 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $465MQ4 ’19Q1 ’20: $323MQ2 ’20: $457MQ3 ’20: $380MQ4 ’20: $297MQ4 ’20Q1 ’21: $555MQ2 ’21: $397MQ3 ’21: $492MQ4 ’21: $533MQ4 ’21Q1 ’22: $458MQ2 ’22: $404MQ3 ’22: $522MQ4 ’22: $372MQ4 ’22Q1 ’23: $391MQ2 ’23: $401MQ3 ’23: $348MQ4 ’23: $377MQ4 ’23Q1 ’24: $447MQ2 ’24: $447MQ3 ’24: $484MQ4 ’24: $419MQ4 ’24Q1 ’25: $264MQ2 ’25: $260MQ3 ’25: $273MQ4 ’25: $318MQ4 ’25Q1 ’26: $360Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 82.7%Other: 10.2%ADR: 7.1%
  • Common Stock · 82.7% · $298M
  • Other · 10.2% · $37M
  • ADR · 7.1% · $26M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2025 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
ALXOALX ONCOLOGY HLDGS INCNEW+3.06M3.06M+$6M$6M
RLYBRALLYBIO CORPNEW+291.8K291.8K+$3M$3M
VRDNVIRIDIAN THERAPEUTICS INCSOLD OUT−736.6K0−$23M$0
ELVNENLIVEN THERAPEUTICS INCSOLD OUT−772.5K0−$12M$0
RALLYBIO CORPSOLD OUT−3.63M0−$2M$0
ERASERASCA INCTRIMMED−1.92M3.49M+$36M$56M
TYRATYRA BIOSCIENCES INCHELD+01.03M+$12M$39M
CAMPCAMP4 THERAPEUTICS CORPHELD+05.87M−$10M$26M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2026

20 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ERASERASCA INChistory →COM15.66%$56M3.49M
2TRDAENTRADA THERAPEUTICS INChistory →COM14.21%$51M4.06M
3TYRATYRA BIOSCIENCES INChistory →COM10.94%$39M1.03M
4CAMPCAMP4 THERAPEUTICS CORPhistory →COM7.19%$26M5.87M
5260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS6.41%$23M580.9K
6PHARVARIS N VCOM6.26%$23M797.6K
7MPLTMAPLIGHT THERAPEUTICS INChistory →COM5.36%$19M950.0K
8TECXTECTONIC THERAPEUTIC INChistory →COM5.21%$19M606.7K
9TCE2CELLDEX THERAPEUTICS INC NEWhistory →COM NEW4.38%$16M497.3K
10ARTVARTIVA BIOTHERAPEUTICS INChistory →COM4.21%$15M2.35M
11EYPTEYEPOINT INChistory →COM NEW3.76%$14M1.05M
12SRZNSURROZEN INChistory →COM NEW3.13%$11M387.5K
13ZNTLZENTALIS PHARMACEUTICALS INChistory →COM2.56%$9M3.95M
14GH RESEARCH PLCORDINARY SHARES2.24%$8M572.7K
15TARAPROTARA THERAPEUTICS INChistory →COM STK1.98%$7M1.37M
16BIOHAVEN LTDCOM1.74%$6M739.0K
17ALXOALX ONCOLOGY HLDGS INChistory →COM1.70%$6M3.06M
18SKYESKYE BIOSCIENCE INChistory →COM NEW1.65%$6M9.68M
19RLYBRALLYBIO CORPCOM0.73%$3M291.8K
20SLNSILENCE THERAPEUTICS PLCADS0.70%$3M476.2K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$360M20May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$318M21Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$273M25Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$260M29Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$264M31May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$419M31Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$484M28Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$447M28Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$447M26May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$377M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$348M26Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$401M24Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$391M24May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$372M21Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$522M21Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$404M21Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$458M19May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$533M17Feb 3, 202213F-HRchanges · EDGAR ↗
Q3 2021$492M16Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$397M12Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$555M11May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$297M10Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$380M9Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$457M9Aug 5, 202013F-HRchanges · EDGAR ↗
Q1 2020$323M8Apr 29, 202013F-HRchanges · EDGAR ↗
Q4 2019$465M9Feb 5, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.